Investors need to pay close attention to About Alkermes (ALKS) stock based on the movements in the options market lately.

Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model.

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise ...

CHICAGO: CG Life has acquired New York City-based Berry & Company Public Relations. The deal, which closed on May 6, expands ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) yesterday ...

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar ...

The Kiwanis Club of Wilmington held its annual Bike Rodeo on Saturday starting at the parking lot of Clinton Memorial ...

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which missed the Zacks Consensus Estimate of 59 cents. The company had ...

"Each year, the spring scientific meetings bring together critical stakeholders from across the field of psychiatry to share insights and advance patient care; Alkermes is honored to have our research ...